Clopidogrel: how good is it and how does it work?

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Atherothrombotic disease complications pose significant risks despite current treatments.
• Long-term antiplatelet therapy has historically relied on aspirin, showing limitations in preventing recurrent events.
• Approximately 75% of high-risk patients experience thrombotic events even with chronic aspirin use.

Purpose of the Study:

• To evaluate the efficacy of newer antiplatelet agents in managing atherothrombotic disease.
• To investigate the benefits of combining clopidogrel with aspirin compared to aspirin monotherapy.
• To explore the mechanistic basis for improved outcomes with combination antiplatelet therapy.

Main Methods:

• Review of clinical trial data comparing aspirin alone versus aspirin plus clopidogrel.
• Analysis of outcomes in patients with atherothrombotic disease receiving different antiplatelet regimens.
• Investigation into the pathways of platelet activation inhibited by clopidogrel.

Main Results:

• Combination therapy with clopidogrel and aspirin demonstrates superior efficacy over aspirin alone.
• Clinical trials confirm significant benefits of dual antiplatelet therapy in reducing thrombotic events.
• Ongoing large-scale trials are further investigating the impact of these therapies.

Conclusions:

• Clopidogrel represents a valuable addition to antiplatelet treatment strategies for atherothrombotic disease.
• The benefit of combination therapy extends beyond simple platelet aggregation inhibition.
• Enhanced protection is achieved by targeting vascular inflammation, endothelial dysfunction, and angiogenesis.